PHARMACEUTICAL FORMULATION 514
The present invention relates to a pharmaceutical formulation comprising the drug 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-be nzyl]-2H-phthalazin-1-one in a solid dispersion with a matrix polymer that exhibits low hygroscopicity and high softening temperature, such as copovidone....
Saved in:
Main Authors | , , , , , , |
---|---|
Format | Patent |
Language | English Spanish |
Published |
02.05.2011
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The present invention relates to a pharmaceutical formulation comprising the drug 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-be nzyl]-2H-phthalazin-1-one in a solid dispersion with a matrix polymer that exhibits low hygroscopicity and high softening temperature, such as copovidone. The invention also relates to a daily pharmaceutical dose of the drug provided by such a formulation. In addition, the invention relates to the use of a matrix polymer that exhibits low hygroscopicity and high softening temperature in solid dispersion with 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-be nzyl]-2H- phthalazin-1-one for increasing the bioavailability of the drug.
La presente invención se refiere a una formulación farmacéutica que contiene el fármaco 4-[3-(4-ciclopropanocarbonil-piperazina-1- carbonil)-4-fluorobencil]-2H-ftalazin-1-ona en una dispersión sólida con un polímero de matriz que tiene baja higroscopicidad y elevada temperatura de ablandamiento, como copovidona. La invención también se refiere a una dosis farmacéutica diaria del fármaco provisto por dicha formulación. Además, la invención se refiere al uso de un polímero de matriz que tiene baja higroscopicidad y elevada temperatura de ablandamiento en una dispersión sólida con 4-[3-(4-ciclopropanocarbonil-piperazina-1-ca rbonil)-4-fluorobencil]-2H-ftalazin-1-ona para aumentar la biodisponibilidad del fármaco. |
---|---|
Bibliography: | Application Number: MX20110003740 |